TYK296: Difference between revisions
https://pedsanesthesia.net/wikiOLD032021>TYK bot Bot: Automated import of articles |
m Text replacement - "<p style="text-align: center;"> About Test Your Knowledge</p>" to "<p style="text-align: center;"> About Test Your Knowledge</p> Category:TYK" |
||
| (One intermediate revision by the same user not shown) | |||
| Line 30: | Line 30: | ||
<p style="text-align: center;">[[TYK295|<Prev Question]] --- [[TYK297|Next Question>]]</p> | <p style="text-align: center;">[[TYK295|<Prev Question]] --- [[TYK297|Next Question>]]</p> | ||
<p style="text-align: center;">[[TYK About | About Test Your Knowledge]]</p> | <p style="text-align: center;">[[TYK About | About Test Your Knowledge]]</p> | ||
[[Category:TYK]] | |||
Latest revision as of 02:34, 25 September 2026
All of the following statements are true about immunosuppressive medications EXCEPT:
a) Corticosteriods are the mainstay of treatment for acute rejection, with calcineurin inhibitors used for steroid-resistant episodes
b) Interleukin-2 is a primarily T-cell produced cytokine that mediates graft rejection
c) Development of insulin-dependent diabetes after transplant is associated with tacrolimus
d) Cytokine release syndrome, characterized by hyperpyrexia, cardiovascular collapse, and pulmonary edema, is most closely associated with IL-2 inhibitors
Click for Answer
Answer
Answer d. Cytokine release syndrome is most commonly associated with antithymocyte and antilymphocyte antibodies, not IL-2 inhibitors.
Notes
- This question originally printed in the Pediatric Anesthesiology Review Topics kindle book series, and appears courtesy of Naerthwyn Press, LLC.